Efficacy and safety of colchicine treatment in patients with COVID‐19: A prospective, multicenter, randomized clinical trial. (2nd February 2022)

• Record Type: Journal Article
• Authors: Pourdowlat, Guitti; Saghafi, Fatemeh; Mozafari, Abolfazl; Sahebnasagh, Adeleh; Abedini, Atefeh; Nabi Meybodi, Mohsen; Salehi Nezamabadi, Ali; Mousavinasab, Seyed Ruhollah; Kiani, Arda; Raji, Hanieh; Soltani, Nadia; Gholmzadeh Baeis, Mehdi; Eidani, Esmaeil; Sadeghi Yakhdani, Abdolrahim; Movaseghi, Fatemeh; Habtemariam, Solomon; Akhoundi Meybodi, Zohreh; Gholinataj Jelodar, Mohsen
• Is Part Of: Phytotherapy research. Volume 36:Number 2(2022)
• Page Start: 891
• Page End: 898
• Publication Date: 2022-02-02
• Subjects: clinical trial -- colchicine -- COVID‐19 -- SARS‐CoV2; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7319
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract: Colchicine has shown clinical benefits in the management of COVID‐19 via its anti‐inflammatory effect. However, the exact role of colchicine in COVID‐19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID‐19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3‐day course of 0.5 mg colchicine followed by a 12‐day course of 1 mg colchicine in combination with standard care or a 15‐day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or continued standard care ( M age, 54.72 [ SD, 15.03] years; 93 [63.1%] men). On day 14, patients in the colchicine/standard care group had significantly higher odds of a better clinical status distribution on chest CT evaluation ( p = .048). Based on NYHA classification, the percentage change of dyspnea on day 14 between groups was statistically significant ( p = .026), indicating a mean of 31.94% change in the intervention group when compared with 19.95% in the control group. According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in COVID‐19 patients if contraindications and precautions are considered and it is prescribed at the right time and in appropriate cases.